{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:47:32Z","timestamp":1759333652792},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,2,23]],"date-time":"2012-02-23T00:00:00Z","timestamp":1329955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s12185-012-1026-9","type":"journal-article","created":{"date-parts":[[2012,2,22]],"date-time":"2012-02-22T11:26:47Z","timestamp":1329910007000},"page":"409-419","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL: a 36-month analysis of a phase I and II study"],"prefix":"10.1007","volume":"95","author":[{"given":"Kensuke","family":"Usuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arinobu","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Oritani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Amagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aira","family":"Wanajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,23]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"1026_CR2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O\u2019Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23:1054\u201361.","journal-title":"Leukemia"},{"key":"1026_CR3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Branford S, Muller MC, Kaeda JS, Foroni L, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 2010;116:3758\u201365.","journal-title":"Blood"},{"key":"1026_CR4","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperly JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3358\u201363.","journal-title":"J Clin Oncol"},{"key":"1026_CR5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.leukres.2010.10.027","volume":"35","author":"T Tauchi","year":"2011","unstructured":"Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, et al. Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res. 2011;35:585\u201390.","journal-title":"Leuk Res"},{"key":"1026_CR6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.hoc.2004.03.001","volume":"18","author":"A Hochhaus","year":"2004","unstructured":"Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin N Am. 2004;18:641\u201356.","journal-title":"Hematol Oncol Clin N Am"},{"key":"1026_CR7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","volume":"93","author":"F Palandri","year":"2008","unstructured":"Palandri F, Castagnetti F, Testoni N, Luatti S, Marzocchi G, Bassi S, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600\u00a0mg: outcome of the patients alive after a 6-year follow-up. Haematologica. 2008;93:1792\u20136.","journal-title":"Haematologica"},{"key":"1026_CR8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","volume":"94","author":"RT Silver","year":"2009","unstructured":"Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743\u20134.","journal-title":"Haematologica"},{"key":"1026_CR9","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.leukres.2010.12.006","volume":"35","author":"T Ono","year":"2011","unstructured":"Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, et al. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leukemia Research. 2011;35:598\u2013603.","journal-title":"Leukemia Research"},{"key":"1026_CR10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","volume":"24","author":"M Yanada","year":"2006","unstructured":"Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460\u20136.","journal-title":"J Clin Oncol"},{"key":"1026_CR11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cncr.25690","volume":"117","author":"HJ Lee","year":"2011","unstructured":"Lee HJ, Thompson JE, Wang ES, Wetzler M. Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2011;117:1583\u201394.","journal-title":"Cancer"},{"key":"1026_CR12","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242\u20139.","journal-title":"Blood"},{"key":"1026_CR13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","volume":"10","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A, La Rosee P, Muller MC, Ernst T, Cross NCP. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle. 2011;10:250\u201360.","journal-title":"Cell Cycle"},{"key":"1026_CR14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","volume":"25","author":"D Bixby","year":"2011","unstructured":"Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25:7\u201322.","journal-title":"Leukemia"},{"key":"1026_CR15","doi-asserted-by":"crossref","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. 2009:461\u201376.","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"1026_CR16","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","volume":"118","author":"S Soverini","year":"2011","unstructured":"Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118:1208\u201315.","journal-title":"Blood"},{"key":"1026_CR17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bbapap.2009.11.008","volume":"1804","author":"PW Manley","year":"2009","unstructured":"Manley PW, Drueckes P, Fendrich G, Furet P, Liebetanz J, Martiny-Baron G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta. 2009;1804:445\u201353.","journal-title":"Biochim Biophys Acta"},{"key":"1026_CR18","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94:1765\u20139.","journal-title":"Br J Cancer"},{"key":"1026_CR19","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","volume":"110","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110:3540\u20136.","journal-title":"Blood"},{"key":"1026_CR20","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz JA, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"1026_CR21","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","volume":"111","author":"P Coutre le","year":"2008","unstructured":"le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008;111:1834\u20139.","journal-title":"Blood"},{"key":"1026_CR22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, et al. A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed\/refractory Ph+ ALL. Int J Hematol. 2009;89:679\u201388.","journal-title":"Int J Hematol"},{"key":"1026_CR23","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1026_CR24","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12185-011-0841-8","volume":"93","author":"H Nakamae","year":"2011","unstructured":"Nakamae H, Shibayama H, Kurokawa M, Fukuda T, Nakaseko C, Kanda Y, et al. Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd. Int J Hematol. 2011;93:624\u201333.","journal-title":"Int J Hematol"},{"key":"1026_CR25","doi-asserted-by":"crossref","unstructured":"Giles F, Larson R, Kantarjian HM, le Coutre P, Palandri F, Haque A, et al. Nilotinib in patients (pts) with philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib (Poster). J Clin Oncol. 2008;26 (supplement; abstract 7017).","DOI":"10.1200\/jco.2008.26.15_suppl.7017"},{"key":"1026_CR26","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","volume":"354","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Giles F, Wunderle L, Bhalla K, O\u2019Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542\u201351.","journal-title":"N Engl J Med"},{"key":"1026_CR27","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041\u201351.","journal-title":"J Clin Oncol"},{"key":"1026_CR28","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1002\/cncr.25351","volume":"116","author":"M Koren-Michowitz","year":"2010","unstructured":"Koren-Michowitz M, le Coutre P, Duyster J, Scheid C, Panayiotidis P, Prejzner W, et al. Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant. Cancer. 2010;116:4564\u201372.","journal-title":"Cancer"},{"key":"1026_CR29","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","volume":"27","author":"T Hughes","year":"2009","unstructured":"Hughes T, Saglio G, Branford S, Soverini S, Kim DW, M\u00fcller MC, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27:4204\u201310.","journal-title":"J Clin Oncol"},{"key":"1026_CR30","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1182\/blood-2005-12-010132","volume":"108","author":"N Bubnoff von","year":"2006","unstructured":"von Bubnoff N, Manley P, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood. 2006;108:1328\u201333.","journal-title":"Blood"},{"key":"1026_CR31","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","volume":"114","author":"S Soverini","year":"2009","unstructured":"Soverini S, Gnani A, Colarossi S, Castagnetti F, Abruzzese E, Paolini S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114:2168\u201371.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1026-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1026-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1026-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T03:06:40Z","timestamp":1561345600000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1026-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,23]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1026-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,23]]}}}